Monitoring the emergence of resistance with sotrovimab in immunocompromised patients with COVID-19: LUNAR study
Open Access
- 19 May 2025
- journal article
- research article
- Published by Elsevier in Journal of Infection
- Vol. 91 (1) , 106510
Abstract
No abstract availableKeywords
Funding Information
- GlaxoSmithKline (218407)
This publication has 28 references indexed in Scilit:
- Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature reviewInfection, 2024
- When It Comes to SARS-CoV-2 Clearance, People Who Are Immunocompromised Are Not All AlikeJAMA, 2024
- Persistent SARS-CoV-2 PCR Positivity Despite Anti-viral Treatment in Immunodeficient PatientsJournal of Clinical Immunology, 2023
- Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancerCancer Cell, 2023
- WHO's Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessedThe Lancet, 2022
- Emergence of Delta and Omicron variants carrying resistance-associated mutations in immunocompromised patients undergoing sotrovimab treatment with long-term viral excretionClinical Microbiology and Infection, 2022
- Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strainsNature Communications, 2022
- Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimabClinical Microbiology and Infection, 2022
- Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19JAMA, 2022
- Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: A systematic literature review and meta-analysisJournal of Infection, 2022